The chart above plots the price of DBVT over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 42 sessions over that window: $18.23 on 26 May 2026 through $13.72 on 24 July 2026.
Market cap$4.1B
52-week range$8.51 – $28
Avg volume50.2K
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 20, 2026
DBVT insider trades
SEC Form 4 · last 90 days · newest reported trade 29 Jul 2026
Open-market buys0
Open-market sells1
Net sold$1K
Non-trade filings0
DateInsiderTypeSharesValue
29 Jul 2026Mohideen PharisChief Medical OfficerSell464$1K
DBVT reported financials
SEC EDGAR XBRL
DBVT reported revenue of $5.6M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$146.9M.
FigureReportedPeriod
Revenue
$5.6M
31 Dec 2025 fiscal year
Net income
−$146.9M
31 Dec 2025 fiscal year
Diluted EPS
−$1.05
31 Dec 2025 fiscal year
Total assets
$223.2M
30 Jun 2026 at period end
Total equity
$160.4M
30 Jun 2026 at period end
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
DBVT earnings
SEC EDGAR
DatePeriodEPSRevenue
30 Jun 2026Q2 2026$-0.12$1M
31 Mar 2026Q1 2026$-0.11$1M
31 Dec 2025FY 2025$-1.05$6M
30 Sep 2025Q3 2025$-0.24$3M
30 Jun 2025Q2 2025$-0.31$2M
31 Mar 2025Q1 2025$-0.26$1M
31 Dec 2024FY 2024$-1.17$4M
30 Sep 2024Q3 2024$-0.32$1M
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
DBVT institutional holders
SEC Form 13F
6 of the 45 institutional funds we track reported a DBVT position for the quarter ended 30 Jun 2026 — a combined $35.4M; the latest of those filings landed 14 Aug 2026.